Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplant with Omidubicel Demonstrates Sustained Clinical Improvement Versus Standard Myeloablative Umbilical Cord Blood Transplantation (UCBT): Final Results of a Phase III Randomized, Multicenter Study
Mitchell E. Horwitz(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Guillermo Sanz(Instituto de Salud Carlos III), David Valcárcel(Vall d'Hebron Hospital Universitari), Corey Cutler(Harvard University), Gary J. Schiller(Fred Hutch Cancer Center), Jaime Sanz(Hospital Universitari i Politècnic La Fe), Claudio G. Brunstein(Hotel Dieu Hospital), Rabi Hanna(Cleveland Clinic), Joseph P. McGuirk(University of Kansas Medical Center), Caroline A. Lindemans(University Medical Center Utrecht), Einat Galamidi-Cohen(Gamida Cell (Israel)), Andrew R. Rezvani(Stanford Blood Center), Liang Piu Koh(National University Cancer Institute, Singapore), Richard T. Maziarz(Oregon Health & Science University), Aurélie Schwarzbach(Gamida Cell (Israel)), William Ying Khee Hwang(Singapore General Hospital), Nicole Karras(City Of Hope National Medical Center), Patrick J. Stiff(Loyola University Medical Center)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k